Pharmaceutical companies Lilly and Novo Nordisk are shifting their focus from the US to international markets for growth in obesity treatments. Lilly's new oral medication, Foundayo, is a significant part of its global strategy to address obesity, a growing health concern worldwide. Novo Nordisk is also pursuing expansion beyond the US to capitalize on increasing demand for effective obesity drugs. This strategic move highlights the companies' recognition of the global potential for obesity treatments and their intent to diversify market presence beyond the traditionally dominant US market. Lilly’s global bet hinges on a new pill called Foundayo. The update was published on 5 Jun 2026, 12:37 pm.